Drug Profile
Research programme: allergy/immunology - Kyorin
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Developer Kyorin Pharmaceutical; Scottish Biomedical
- Class
- Mechanism of Action Immunomodulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity; Immunological disorders; Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in Scotland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Scotland
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Scotland